---
document_datetime: 2023-09-21 20:49:36
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/repaglinide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: repaglinide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.5110245
conversion_datetime: 2025-12-17 14:32:45.804824
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Repaglinide Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0015              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 13/12/2021                          |                                             | SmPC, Annex II, Labelling and PL |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0014     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                  | 16/02/2021   |            | Annex II and PL                  |      |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------|
| IAIN/0013/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                | 22/01/2020   | n/a        |                                  | site |
| IAIN/0012   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                     | 14/09/2016   | 28/04/2017 | Annex II and PL                  |      |
| IB/0011/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 25/05/2016   | 28/04/2017 | SmPC, Annex II, Labelling and PL |      |

<div style=\"page-break-after: always\"></div>

|             | product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                      |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0010/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a | 12/11/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                      |
| T/0009      | Transfer of Marketing Authorisation from Teva Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                         | 03/11/2014 | 21/11/2014 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                      |
| R/0008      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                 | 25/04/2014 | 19/06/2014 |                        | This is a renewal of the Marketing Authorisation for a generic product. During the renewal period no significant information has arisen that alters the overall assessment of the benefit/risk balance of Repaglinide Teva. The CHMP recommends that the renewal be granted with unlimited validity. |
| IA/0007     | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size                                                                                                                                                                                                                                               | 25/02/2013 | n/a        |                        |                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IAIN/0006/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/12/2012   | 18/12/2013   | Annex II and PL                  |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|
| IB/0005       | Updated section 4.5 of the SmPC in order to include a new drug-drug interaction with deferasirox. Section 2 of the Package Leaflet has been updated accordingly. The Product Information has also been updated in line with the latest QRD template (version 8). The MAH also took this opportunity to update some of the contact details for local representatives in the Package Leaflet (Estonia, Finland, Germany, Iceland, Ireland, Norway and Romania). C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 28/06/2012   | 29/10/2012   | SmPC, Annex II, Labelling and PL |
| IA/0004       | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 24/04/2012   | n/a          |                                  |

<div style=\"page-break-after: always\"></div>

| IA/0003/G   | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the process of an immediate release solid   | 02/08/2011   | n/a   | Annex II and PL   | manufacturing oral dosage form   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------|----------------------------------|
| N/0002      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/03/2011   | n/a   | Annex II and PL   |                                  |
| IA/0001     | To replace a secondary packaging site for Repaglinide Teva finished product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 18/12/2009   | n/a   |                   |                                  |

<div style=\"page-break-after: always\"></div>

| IA_07_a_Replacement/add. of manufacturing site:   |
|---------------------------------------------------|
| Secondary packaging site                          |